Justifying the choice of endpoints for clinical trials

Journal of the National Cancer Institute

Volumn 105, Issue 21, 2013, Pages 1594-1595

  Begg, Colin B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; CANCER CONTROL; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DISEASE FREE SURVIVAL; EDITORIAL; EFFECT SIZE; MEDICAL DECISION MAKING; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOLID TUMOR; STOMACH CANCER; SYSTEMIC THERAPY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; GASTRECTOMY; HUMANS; NEOPLASM RECURRENCE, LOCAL; STOMACH NEOPLASMS;

EID: 84890478483     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt289     Document Type: Editorial

References (9)

1. Fleming TR. Surrogate markers in AIDS and cancer trials. Stat Med. 1994;13(13-14):1423-1435.
2. Ellenberg S. Discussion of "Surrogate markers in AIDS and cancer trials." Stat Med. 1994;13(13-14):1437-1440.
3. US Food and Drug Administration. Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. http://www.fda.gov/ cber/guidelines.htm. Accessed September 25, 2013.
4. European Medicines Agency. Guideline on the Evaluation of Anticancer Medicinal Products in Man. http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2009/12/WC500017748.pdf. Accessed September 25, 2013.
5. Oba K, Paoletti X, Alberts S, et al. Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: A meta-Analysis. J Natl Cancer Inst. 2013;105(21):1600-1607.
6. Paoletti X, Oba K, Bang YJ, et al. Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: A meta-Analysis. J Natl Cancer Inst. 2013;105(21):1667-1670.
7. Grothey A. Surrogate endpoints for overall survival in early colorectal cancer from the clinician's perspective. Stat Methods Med Res. 2008;17(5):529-535.
8. Booth CM, Eisenhauer EA. Progression-free survival: meaningful or simply measurable? J Clin Oncol. 2012;30(10):1030-1033.
9. Buyse M, Burzykowski T, Carroll K, et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol. 2007;25(33):5218-5224.